Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1693

Novel Pneumococcal Vaccine with Adjuvant Properties

Inventors: Richard Malley, Ying-jie Lu

Invention Types: Therapeutics

Research Areas: Immunology, Neonatology/Pediatric, Infectious Disease

Keywords: Composition of Matter, Method of Use, Vaccine

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Streptococcus pneumoniae (pneumococcus) is a leading cause of mortality worldwide, claiming the lives of over 1 million children each year in developing countries and resulting in serious morbidity and mortality in developed countries and over 50% of deaths in influenza pandemics are estimated to be due to pneumococcal pneumonia or sepsis.


Dr. Malley and Dr. Lu have developed a new fusion-conjugate vaccine that elicits potent immunity to pneumococcus and unlike other vaccines on the market, fulfills all the criteria for use in both developing and developed countries: (i) coverage of all S. pneumoniae strains, (ii) generation of both B cell – antibodies - and T cell -IL-17A- responses to the organism, (iii) immunity against both invasive disease and mucosal carriage, (iv) lower cost and greater ease of manufacture, and (v) an intellectual property position providing freedom to operate.


An important strength of this invention is that the construct can be readily adapted for use as vaccines against other pathogens with ease, constituting a vaccine platform.

Applications:

Affordable, broadly and highly protective vaccine for S. pneumoniae strains world-wide

Competitive Advantages:

A single vaccine specific to all strains of Pneumococcus, cheaper and simpler to produce than the current conjugate vaccine, self-adjuvanting, based on antigen common to all Pneumococcus strains, unlikely to induce serotype replacement.

Business Opportunity:

1- Exclusive or non-exclusive licenses to therapeutic companies

2- Collaborations and Sponsored Research

Key Publications: Lu, Forte, Thompson, Anderson, Malley. 2009. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infection and Immunity. May 77(5):2076-83.

IPStatus: Pat. Pend.